Two optical methods were used simultaneously to evaluate the effect of a vasoactive drug hydralazine on oxygenation and blood flow in SA-1 tumors in A/J mice. A novel luminescence-based optical sensor (OxyLite instrument, Oxford Optronix, UK) was used to monitor partial pressure of oxygen (pO2) in tumors. Laser Doppler flowmetry was used to assess relative blood perfusion in tumors. Measurement...

The hydrazinophthalazines-derivates (syn. hydrazine) hydralazine and dihydralazine were approved by the FDA as anti-hypertensives in 1953 – and because they are both effective and safe they are among the oldest drugs which have kept their place in clinical practice. While hydrazine was originally discovered as potent vasodilatator which lowered blood pressure and increased renal perfusion, it r...

The haemodynamic effects of hydralazine were studied in seven infants and a child, each with a large ventricular septal defect. Hydralazine, 0.3 mg/kg, was administered intravenously. This caused a lowering of pulmonary arterial pressure from 57 +/- 4 mmHg to 49 +/- 4 mmHg, and a lowering of left atrial pressure from 12 +/- 1 mmHg to 10 +/- 1 mmHg. Systemic vascular resistance was reduced from ...

Hydralazine hydrochloride has a half-life of 2 to 4 hours with an oral bioavailability of 26-50%. Since hydralazine has a demethylating effect on various suppressor genes, it can be used in various types of cancer to support chemotherapy. The purpose of this study was to optimize and evaluate floating tablets of hydralazine hydrochloride designed to prolong the gastric residence time and to pro...

The acute pulmonary and systemic haemodynamic response to low (0.15 mg/kg) and high (0.30 mg/kg) doses of intravenous hydralazine was evaluated in 26 consecutive patients with severe pulmonary hypertension due to cor pulmonale (nine patients), primary pulmonary hypertension (11 patients), or pulmonary embolism (six patients). Hydralazine did not cause a significant change in pulmonary arterial ...

Antihypertensive drug treatment is capable of aggravating angina pectoris in hypertensive patients with coronary artery disease. The complication appears to be due to different hemodynamic mechanisms. Angina pectoris caused by hydralazine may result not only from a reduction in aortic perfusion pressure but also from increases in cardiac output and pulse rate which the drug produces. Coronary i...

Antihypertensive drug treatment is capable of aggravating angina pectoris in hypertensive patients with coronary artery disease. The complication appears to be due to different hemodynamic mechanisms. Angina pectoris caused by hydralazine may result not only from a reduction in aortic perfusion pressure but also from increases in cardiac output and pulse rate which the drug produces. Coronary i...

We studied the effect of hydralazine, an antihypertensive drug with lupus-inducing side effects, on the conformation ofpoly(dGm5dC) poly(dG-m5dC) and a plasmid with a 23 bp insert of (dGdC)" * (dG-dC). sequences. Using an e.l.i.s.a. with a monoclonal anti-(Z-DNA) antibody Z22, we found that hydralazine provoked the Z-DNA conformation in poly(dG-m5dC) -poly(dGm5dC) at 250-500 1uM concentration. ...

Drug induced lupus erythematosus (DIL or DILE) is an autoimmune disorder caused by chronic use of certain drugs. We report a unique case of hydralazine induced lupus syndrome (HILS) with a negative antinuclear antibody in a female patient who was on hydralazine for a period of 1.5-2 years and developed recurrent pericardial effusion as a result of it. Initially her condition was managed with a ...